Status:
TERMINATED
FBnTP Imaging of Breast Cancer
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions:
Breast Cancer
Eligibility:
FEMALE
26+ years
Phase:
PHASE1
Brief Summary
Our preclinical studies suggest the capacity of the positron emission tomography imaging agent 18F-fluorobenzyl triphenyl phosphonium (FBnTP) to detects early-stage small breast tumors (e.g., DCIS), a...
Detailed Description
Breast cancer is the most widespread type of cancer among women in the USA, and the second leading cause of death. The National Cancer Institute estimates that in 2013, in the USA, 226,870 women will ...
Eligibility Criteria
Inclusion
- Female patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e., index cancer)
- Age \> 25 Ability and willingness to sign informed consent prior to any study procedure.
- Positive indication of disease on mammogram or MRI scan.
- Candidate for breast cancer surgery on the basis of recommendation of a breast cancer surgeon.
- Ability to undergo up to 90 minutes of PEM imaging.
Exclusion
- Any active or chronic illness that, in the opinion of the investigators, would make the study unsafe or limit compliance with study procedures.
- Past or present history of active substance abuse (drug or alcohol).
- Inability to tolerate venous access.
- Pregnant females are excluded from this study. All females of child-bearing potential will undergo a serum pregnancy test within 48 hours prior to FBnTP administration.
Key Trial Info
Start Date :
March 12 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 13 2021
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT02204462
Start Date
March 12 2015
End Date
December 13 2021
Last Update
December 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287